HEALTHSTAT NEWS
Biotech exec Jeremy Levin on the industry’s strategic turning point
Jeremy Levin's new book 'Biotech in the Balance' addresses challenges facing the biotech industry and offers a roadmap for its future. The article also recaps recent biotech developments, including Eli Lilly's gene-editing treatment for high cholesterol and a longevity startup's funding.
Related Signal
Adjacent reporting
- STAT+: Biotech veteran Jeremey Levin on why the industry’s future is secure, but American leadership is at risk
- STAT+: Five biotech news updates to stay on top of today
- STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
- Opinion: STAT+: Pharma and biotech leaders are destroying their own industry
- Guarding biotech from China and big bets in longevity
- STAT+: Pharmalittle: We’re reading about biotech investors’ mood, a former FDA head’s confidence, and more